WHO ICTRP trial
A multicentre study to standardise the management of relapsed acute…
CTRI/2019/10/021758 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2019/10/021758 |
|---|---|
| Public title | A multicentre study to standardise the management of relapsed acute lymphoblastic leukaemia in children and young people |
| Scientific title | The Indian Paediatric Oncology Group collaborative multicentre treatment protocol for children and adolescents with relapsed acute lymphoblastic leukaemia (InPOG ALL R1) - InPOG ALL R1 |
| Primary sponsor | Tata Medical Center |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | India |
| Conditions | Health Condition 1: C910- Acute lymphoblastic leukemia [ALL] |
| Interventions | Intervention1: A risk-adapted bortezomib and reduced intensity cytarabine-based modified ALL R3 treatment protocol for relapsed acute lymphoblastic leukaemia: Bortezomib in induction and reduced cumulative high-dose cytarabine in… |
| Registration date | Oct 22, 2019 |
| Target size | 220 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: